Vogelmeier, Claus F.
Claus Vogelmeier Claus F. Vogelmeier
VIAF ID: 305940235 (Personal)
Permalink: http://viaf.org/viaf/305940235
Preferred Forms
- 100 0 _ ‡a Claus Vogelmeier ‡c Claus F. Vogelmeier
- 100 1 _ ‡a Vogelmeier, Claus F.
- 100 1 _ ‡a Vogelmeier, Claus F.
- 100 1 _ ‡a Vogelmeier, Claus F.
-
- 100 1 _ ‡a Vogelmeier, Claus F.
4xx's: Alternate Name Forms (4)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Aclidinium, Formoterol-Fixkombination | |
Aktuelle Erkenntnisse zur medikamentösen Therapie der COPD Unterscheidung zwischen COPD und Asthma ; Intensität der COPD-Therapie ; Kombinationstherapie mit LABA und LAMA | |
Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET | |
Bestimmung antigenspezifischer IgG-Antikörper mit dem IgG-RAST | |
Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma | |
Choroby układu oddechowego w praktyce lekarza rodzinnego | |
Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients | |
COPD maintenance medication is linked to left atrial size Results from the COSYCONET cohort | |
The discovery of α1-antitrypsin and its role in health and disease | |
Dynamics of heart rate and sleep stages in normals and patients with sleep apnea | |
Effektiv gegen die COPD bei Tag und Nacht | |
Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. | |
Efficacy of indacaterol in the treatment of patients with COPD. | |
Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography | |
Erratum to: Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management | |
European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. | |
The EvA study: aims and strategy. | |
Exposure of differentiated airway epithelial cells to volatile smoke in vitro | |
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts | |
Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study | |
Gardening can induce pulmonary failure: Aspergillus ARDS in an immunocompetent patient, a case report | |
The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline | |
[The German Respiratory Society's Guideline for the Diagnosis and Treatment of Patients with Acute and Chronic Cough] | |
Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany | |
Guidelines for diagnosis and therapy of patients with asthma 2005. The most important aspects for adults | |
Highlights and hot topics in the management of COPD: where are we heading? | |
Imatinib-associated pulmonary alveolar proteinosis | |
Impact of different definitions of airflow limitation on the prevalence of chronic obstructive pulmonary disease in the general population. | |
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis | |
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. | |
Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus | |
[Intermediate care units and noninvasive ventilation] | |
Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency | |
Lichenoid exanthema mimicking graft-versus-host disease associated with obstructive lung disease in a non-transplanted patient | |
Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease | |
Microbial DNA induces a host defense reaction of human respiratory epithelial cells | |
Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. | |
Nonrandom variability of respiration during sleep in healthy humans. | |
Obstructive sleep apnea patients can be identified by ion mobility spectrometry-derived smell prints of different biological materials. | |
An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. | |
Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. | |
Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report | |
Outcomes in clinical trials | |
Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study | |
Perception of symptoms and quality of life - comparison of patients' and physicians' views in the COPD MIRROR study | |
Peripheral arterial tonometry, oximetry and actigraphy for ambulatory recording of sleep apnea. | |
Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe | |
Pharmacological treatment of COPD: the devil is always in the detail. | |
Phosphodiesterase-4-Hemmer-Roflumilast Fortschritt bei der Therapie der COPD | |
Pneumologie für die Praxis | |
Pneumologische Notfälle vom Leitsymptom zur Diagnose - von der richtigen Diagnose zur effektiven Therapie ; mit 95 Tabellen | |
Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease | |
Prolastin Alpha-1-Antitrypsin-Mangel | |
The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods | |
Pulmonary abscess with bacteremia in a young man. | |
"Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD | |
Recombinant Sendai virus for efficient gene transfer to human airway epithelium | |
Regional differences in prediction models of lung function in Germany | |
Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort | |
Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies | |
Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015. | |
A review of national guidelines for management of COPD in Europe | |
Sex differences in alpha-1-antitrypsin deficiency lung disease-analysis from the German registry | |
Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial | |
Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies - A Novel Stepwise Approach by Evaluation of Medication | |
Therapie-Handbuch Pneumologie | |
Tiotropium versus salmeterol for the prevention of exacerbations of COPD. | |
TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer | |
Tracheostomy and related host-pathogen interaction are associated with airway inflammation as characterized by tracheal aspirate analysis | |
Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort | |
Treatable traits: toward precision medicine of chronic airway diseases | |
Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. | |
Validity and usability of physical activity monitoring in patients with chronic obstructive pulmonary disease (COPD) | |
Whole-body vibration therapy in intensive care patients: A feasibility and safety study | |
Wichtigste für Klinik und Praxis | |
Work of Breathing in Fixed and Pressure Relief Continuous Positive Airway Pressure (C-Flex™): A post hoc Analysis | |
A year in the life of German patients with COPD: the DACCORD observational study |